The type 1 insulin-like growth factor receptor (IGF1R) is overexpressed by malignant melanomas compared with benign naevi, and mediates proliferation, motility and protection from apoptosis. However, the utility of IGF1R targeting as anti-cancer therapy may be limited by activating mutations in downstream signaling intermediates. We previously showed that IGF1R knockdown blocked survival of prostate cancer cells in which Akt activation was deregulated by PTEN loss. The current study investigated effects of IGF1R targeting in cells harboring activating RAS-RAF mutations, found in 70-80% of human melanomas. We assembled a panel of eight human melanoma cell lines: two expressing wild-type (WT) B-RAF and N-RAS, two with activating N-RAS mutations and four harboring V600E B-RAF. We also generated isogenic cell populations overexpressing WT or V600E B-RAF. Cells expressing V600E B-RAF were relatively resistant to apoptosis. However, IGF1R gene silencing was capable of inducing significant inhibition of survival, enhancement of apoptosis, and Btwo-fold sensitization to cisplatin and temozolomide. These effects were independent of mutation status and were associated with reduced activation of Akt and also, unexpectedly, of ERKs. These results support development of IGF1R targeting as therapy for melanoma, regardless of the presence of activating mutations in the RAS-RAF pathway.
Introduction
The type 1 insulin-like growth factor receptor (IGF1R) mediates many functions required for the maintenance of the malignant phenotype including proliferation and survival, and is an attractive anti-cancer treatment target (Baserga et al., 1997; Bohula et al., 2003a; Garber, 2005) . The effect on survival is mediated via multiple signaling intermediates, principally the phosphatidylinositol-3 kinase (PI3K)-Akt pathway and also the RAS-RAF-mitogen-activated protein kinase (MAPK) pathway (Peruzzi et al., 1999; LeRoith, 2000; O'Connor, 2003) . It is increasingly recognized that tumor cells harbor activating mutations in downstream signaling intermediates that could render them refractory to inhibition of cell signaling at the receptor level (Macaluso et al., 2002; Camp et al., 2005) . We previously investigated the effect of activation of the PI3K-Akt pathway on sensitivity to IGF1R targeting in human prostate cancer cells. IGF1R gene silencing was shown to induce significant survival inhibition and also sensitized to DNA-damaging cytotoxic drugs (Rochester et al., 2005) . These effects were independent of the presence of wild-type (WT) PTEN, a tumor suppressor gene encoding a phosphatase that antagonizes the effects of PI3K (McMenamin et al., 1999) . The absence of functional PTEN was associated with basal Akt phosphorylation, but this pathway retained a degree of IGF-sensitivity, and its activity was inhibited by IGF1R knockdown. These findings suggest that IGF1R targeting remains effective in tumor cells with deregulated PI3K-Akt signaling (Rochester et al., 2005) .
Mutations in the RAS or RAF genes lead to constitutive activation of MAPKs, and contribute to the development of many human cancers (Bos, 1989) . Mutations in the B-RAF and N-RAS genes occur in approximately 75% and 15% of malignant melanomas, respectively (Brose et al., 2002; Davies et al., 2002; Dong et al., 2003; Gorden et al., 2003) , suggesting important roles for these oncogenes in melanocyte biology and disease. B-RAF is a member of the RAF family of serine/threonine cytoplasmic kinases, and serves, along with C-RAF (also termed RAF-1) and A-RAF, as immediate effectors of the RAS GTPases (Hagemann and Rapp, 1999) . RAS proteins recruit RAFs to the plasma membrane, where they initiate activation of extracellular signal-regulated kinases (ERKs) that ultimately regulate gene expression via phosphorylation of transcription factors including Elk-1 and Fos (Marshall, 1994) . The B-RAF missense mutation V600E (initially mis-assigned as V599E; Wellbrock et al., 2004a) accounts for more than 90% of mutated B-RAF alleles (Davies et al., 2002; Kumar et al., 2003) . Substitution of a valine with negatively charged glutamic acid in the B-RAF kinase activation loop converts B-RAF into a constitutively active kinase (Wan et al., 2004) . This causes persistent activation of ERKs, independent of ligand-induced activation of growth factor receptors including the IGF1R.
Because of the frequency of B-RAF and N-RAS mutations in melanoma, we selected this tumor type as a model in which to explore effects of RAS-RAF activation on sensitivity to IGF1R targeting. Malignant melanoma is the most aggressive form of skin cancer and its incidence has increased rapidly over the last 50 years (Jemal et al., 2005) . Melanoma is highly resistant to conventional anti-cancer treatments including radiotherapy and cytotoxic drugs, and there is clearly an urgent need for more effective therapy for this disease. The IGF1R is overexpressed in malignant melanoma compared with benign naevi (Kanter-Lewensohn et al., 2000) . IGF1R antisense oligonucleotides have been shown to inhibit melanoma cell survival in vitro and growth of FO-1 melanoma xenografts in nude mice (Resnicoff et al., 1994) ; the B-RAF status of these cells is unknown. We have shown that antisense-mediated IGF1R downregulation causes tumor growth delay and enhances radiosensitivity of murine B16.F1 melanoma (Macaulay et al., 2001) . These findings suggest that the IGF1R is an attractive target for melanoma treatment. However, the identification of activating RAS-RAF mutations casts doubt on the efficacy of targeting the IGF1R, an upstream signaling element, in human melanoma. Indeed, we predicted that ligandindependent ERK phosphorylation would render melanoma cells refractory to the effects of IGF1R gene silencing. In fact, this study demonstrates that IGF1R knockdown is capable of inducing significant survival inhibition and enhancement of apoptosis, regardless of B-RAF mutation status. These effects are associated with attenuation of IGF signaling via Akt and ERKs, and with enhancement of sensitivity to cisplatin and temozolomide, two drugs with clinical activity in advanced melanoma. These results suggest that IGF1R targeting may be an effective therapeutic approach in the treatment of melanoma and other tumor types harboring activating mutations in the RAS-RAF-MAPK signaling pathway.
Results and discussion
IGF1R gene silencing inhibits signaling and survival of CHL-1 human melanoma cells that express WT B-RAF and N-RAS Initially, we investigated effects of IGF1R knockdown in the context of WT N-RAS and B-RAF. In CHL-1 melanoma cells, there was clear suppression of IGF1R protein levels 48 h after transfection with IGF1R siRNA at concentrations of 1 nM and above ( Figure 1a ). IGF1R protein knockdown caused inhibition of Akt phosphorylation (Figure 1a) , comparable with results we reported in breast and prostate cancer cells (Bohula et al., 2003b; Rochester et al., 2005) ; this was associated with dosedependent inhibition of survival (Figure 1b) . There was no difference in survival between control-transfected and untreated or mock-transfected cultures (not shown), suggesting that siRNA transfection was not associated with nonspecific toxicity in these cells. Serial assessment after IGF1R knockdown showed that IGF1R levels reached their lowest 1-3 days post-transfection (approximately 10% of levels in cultures transfected with the control duplex), and remained below 70% for at least 6 days ( Figure 1c ). CHL-1 cells contained low levels of phosphorylated ERKs (Figure 1c ). An increase in ERK phosphorylation was observed 48 h posttransfection. This was similar to effects we previously observed following IGF1R knockdown in prostate cancer cells (Rochester et al., 2005) and may be related 
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to the reported role of ERKs in apoptosis induction (Xia et al., 1995; Xiao et al., 2005) . However, this was a transient effect, with subsequent suppression of ERK phosphorylation 3-6 days after IGF1R knockdown ( Figure 1c ).
IGF1R knockdown inhibits survival of human melanoma cells that harbor activating mutations in the RAS-RAF-MAPK pathway Next, we investigated the effect of activating mutations in the RAS-RAF-MAPK pathway on the response to IGF1R targeting. We analysed a panel of eight human melanoma cell lines, including two that were WT for both B-RAF and N-RAS, two harboring activating N-RAS mutations and four with the common V600E B-RAF mutation. The occurrence of these mutations appeared to be mutually exclusive, consistent with previous findings (Brose et al., 2002; Davies et al., 2002) . All cell lines expressed the IGF1R, with variation in absolute levels between cell lines, but there was no apparent relationship between IGF1R levels and B-RAF or N-RAS mutational status ( Figure 2a ). In the cell lines harboring activated N-RAS or B-RAF, ERK phosphorylation was detectable in serum-starved cells, and was unresponsive to IGF-stimulation ( Figure 2b ). In all eight cell lines the IGF1R was effectively knocked down by IGF1R siRNA transfection ( Figure 2c ). We predicted that the expression of activated N-RAS or B-RAF would render melanoma cells resistant to the effects of IGF1R knockdown. However, we observed significant inhibition of cell survival in all cell lines, with no clear difference between mutational groups ( Figure 2d ). The ability of cells to survive anchorageindependence is a parameter that has been closely linked to IGF1R function (Baserga et al., 1997) . However, we observed more profound survival inhibition under anchorage-dependent conditions (20-40% of survival in control-transfected cultures) than in anchorageindependence (30-75%). It is possible that residual IGF1R was sufficient to mediate anchorage-independence, and indeed the most profound inhibition of anchorage-independent survival was achieved in three cell lines, CHL-1, ME and SK mel 28, in which we could consistently knockdown the IGF1R to B10% of control levels or lower (Figure 2c and d) . Overall, these results suggest that B-RAF or N-RAS mutation does not render cells refractory to IGF1R targeting.
Effects of IGF1R knockdown in isogenic cells overexpressing WT or V600E B-RAF To remove variation between cell lines, we transfected constructs incorporating myc-tagged WT or V600E B-RAF cDNA into CHL-1 melanoma cells that express WT B-RAF and N-RAS. Empty-vector-transfected CHL-1 cells retained ligand-sensitivity in the MAPK pathway, showing IGF-induced ERK phosphorylation (Figure 3a) . Isogenic cell populations overexpressing WT or V600E B-RAF showed constitutive ERK phosphorylation, with no detectable response to ligand. Transfection of mutant B-RAF had a more striking effect than WT B-RAF, recapitulating the effect of endogenous V600E B-RAF expression (compare Figures 2b and 3a) . Next, we determined the influence 
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AH Yeh et al of B-RAF mutation status on the response to IGF1R knockdown. Consistent with data shown in Figure 2d , IGF1R knockdown inhibited survival under both anchorage -dependent and -independent conditions (Figure 3b and c) . This was associated with enhanced susceptibility to apoptosis, measured by caspase 3/7 activation ( Figure 3d ). It was clear that V600E B-RAF expression conferred relative protection from apoptosis compared with empty vector or WT B-RAF-transfected CHL-1 cells (Figure 3d ). None-the-less IGF1R gene silencing was capable of inducing significant effects on both survival and apoptosis, even in V600E B-RAF transfectants (Figure 3b, c and d) . These results suggest that B-RAF mutation status does not predict responsiveness to IGF1R gene silencing or its effect on cell survival and apoptosis induction.
IGF1R knockdown attenuates Akt and ERK signaling, even in cells overexpressing V600E B-RAF Next, we determined the molecular basis for survival inhibition by IGF1R gene silencing in melanoma cells expressing V600E B-RAF. We predicted that IGF1R knock-down was inhibiting signaling via other pathways including PI3K-Akt that have a major influence on survival (Peruzzi et al., 1999) . Indeed blockade of the PI3K-Akt pathway was shown to be capable of inducing apoptosis and inhibiting melanoma tumor development (Stahl et al., 2004) . In CHL-1 cells transfected with empty vector or WT B-RAF, we observed a decrease in Akt phosphorylation two days post-transfection with IGF1R siRNA (Figure 4a ). There was no evidence of similar responses in V600E transfectants, providing no clear basis for the observed survival inhibition. Similarly there was no detectable change in the phosphorylation status of p38 MAPK (not shown), and no change in levels of RAF kinase inhibitor protein (RKIP; Figure 4 ), a recently reported negative regulator of RAF-1 and B-RAF kinases (Park et al., 2005) . However, six days after induction of IGF1R gene silencing there was clear suppression of Akt phosphorylation in all three transfected CHL-1 cell populations (Figure 4b ). Furthermore this was accompanied by definite inhibition of ERK activation, not only in cells expressing or overexpressing WT B-RAF, but also, unexpectedly, in cells that had been transfected with V600E B-RAF (Figure 4b ). We hypothesize that ERK phosphorylation may be inhibited, despite continued expression of activated B-RAF, as a result of cross-talk from the PI3K-Akt pathway IGF1R targeting in V600E B-RAF melanoma AH Yeh et al (Moelling et al., 2002) . Consistent with this, 3-phosphoinositide-dependent protein kinase-1 (PDK1) has been shown to phosphorylate the activation loop of MEK1/2 (Sato et al., 2004) . Thus, IGF1R targeting was capable of blocking survival signals mediated by both Akt and ERKs, and these effects were manifest not only in melanoma cells expressing WT B-RAF but also V600E B-RAF. It is clear that the majority of human melanomas are dependent on constitutive activation of the RAS-RAF-MAPK pathway. The potential therapeutic relevance of ERK inhibition in the context of B-RAF activation was highlighted by a recent report of potent anti-proliferative responses to MEK inhibitors in human melanomas (Solit et al., 2005) . Our findings suggest that similar inhibition of ERK activation can be achieved by IGF1R knockdown. It will be important to assess whether these findings hold true in vivo, and in the context of IGF1R inhibition induced by blocking antibodies or kinase inhibitors.
IGF1R knockdown enhances sensitivity to cytotoxic drugs used in the treatment of melanoma
The IGF axis has a well-recognized role in protection from apoptosis induced by cytotoxic drugs (Geier et al., 1995; Sell et al., 1995; Dunn et al., 1997; Gooch et al., 1999) . IGF1R targeting has been linked with enhancement of chemosensitivity in several tumor cell types including breast cancer and Ewing's sarcoma (Min et al., 2003; Benini et al., 2004) . We have demonstrated previously that antisense or siRNA-induced IGF1R downregulation led to enhancement of sensitivity to DNA-damaging cytotoxic drugs and ionizing irradiation in human prostate cancer cells and murine melanoma (Macaulay et al., 2001; Rochester et al., 2005) . Given the highly chemo-resistant nature of human melanomas, it was important to assess the effect of IGF1R gene silencing on sensitivity to cytotoxic drugs. We elected to evaluate effects on sensitivity to two drugs, cisplatin and temozolomide, which are used in clinical treatment of advanced melanoma. Cisplatin induces cell death via induction of inter-and intrastrand DNA cross-links (Wang and Lippard, 2005) . In CHL-1 cells, cisplatin caused dose-dependent killing of human melanoma cells, regardless of B-RAF mutation status, and at all drug concentrations cell survival was significantly reduced following IGF1R knockdown ( Figure 5a and Table 1 ). In EV-transfectants, the mean IC 50 values for control-transfected and IGF1R siRNAtransfected cells were 1290 and 573 nM, respectively (Po0.05), representing 2.3-fold sensitization to cisplatin. Equivalent differences were seen in cells transfected with WT B-RAF (1300, 557 nM, Po0.05) and V600E B-RAF (1223, 525 nM, Po0.05), representing 2.4-and 2.6-fold sensitization to cisplatin, respectively ( Figure 5a and Table 1 ).
Temozolomide is a relatively new monofunctional DNA alkylating agent used to treat gliomas and malignant melanoma (Danson and Middleton, 2001; Danson et al., 2003) . IGF1R knockdown induced approximately 1.7-fold sensitization (Po0.001) to temozolomide in CHL-1 cells transfected with empty vector or WT or mutant B-RAF (Figure 5b and Table 1 ). It was notable that V600E B-RAF expression conferred a demonstrable advantage in terms of apoptosis resistance (Figure 3d ; (Hingorani et al., 2003; Wellbrock et al., 2004b; Sharma et al., 2005) , but did not appear to influence chemosensitivity (Figure 5 ), suggesting that B-RAF activation may not provide a molecular basis for the low response rate of malignant melanoma to conventional treatments. It was also clear that IGF1R knockdown was capable of inducing enhancement of sensitivity to two important cytotoxic drugs used in the systemic therapy of metastatic melanoma, and this effect was independent of B-RAF mutation status (Table 1 ).
In conclusion, we have shown that effective IGF1R gene silencing induced profound inhibition of cell survival and enhancement of apoptosis and chemosensitivity in eight human melanoma cell lines, and in isogenic cells derived from a WT B-RAF host, regardless of N-RAS or B-RAF mutation status. These results suggest that RAS-RAF-MAPK activation does not render melanoma cells refractory to IGF1R targeting, at least in vitro, and provides the rationale for the development of IGF1R inhibition as treatment for patients with metastatic melanoma.
Materials and methods

Cell lines
A panel of eight human melanoma cell lines was assembled and DNA sequencing performed to confirm their B-RAF and N-RAS mutation status. CHL-1 and SK mel 23 were WT for both B-RAF and N-RAS, and HMCB and SK mel 2 had activating mutations (Q61K and Q61R, respectively) in codon 61 of N-RAS. A2058, ME, SK mel 28 and SK mel 29 harbored Table 1 .
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Plasmid and siRNA transfections
This study used the R4 IGF1R siRNA designed following a screen for accessible sites in the IGF1R transcript (Bohula et al., 2003b; Rochester et al., 2005) , and a non-silencing control sequence: sense strand 5 0 -UUCUCCGAACGUGU CACGUTT-3 0 , antisense strand 5 0 -ACGUGACACGUUCG GAGAATT-3 0 (Qiagen, Chatsworth, CA, USA). The siRNAs were synthesized at Qiagen and were transfected using Oligofectamine (Invitrogen, Carlsbad, CA, USA) as described previously (Bohula et al., 2003b) . Following 24-48 h incubation at 371C the cells were re-seeded for survival, apoptosis or chemosensitivity assays, or lysed for western blot analysis. Some cultures were serum-starved overnight and stimulated with 50 nM longR3 IGF-I (Gropep, Adelaide, Australia) or diluent for 15 min at 371C. Cell lysates were analysed by SDS-PAGE and immunoblotting as described (Hellawell et al., 2003; Rochester et al., 2005) , using antibodies to IGF-1Rb, phosphorylated T202/T204 ERK1/2, total ERK1/2, phosphorylated S473 Akt (Cell Signaling, Berverly, MA, USA), B-RAF, total Akt (BD Biosciences, Bedford, MA, USA) and b-tubulin (Sigma, St Louis, MO, USA). IGF1R levels were quantified by densitometry after correcting for b-tubulin loading on immunoblots of three individual experiments.
Expression plasmids encoding myc-tagged WT or V600E B-RAF were kindly provided by Dr Richard Marais (Institute of Cancer Research, London, UK). CHL-1 cells were transfected using the Genejuice transfection reagent (EMD Biosciences/Novagen, Madison, MA, USA), according to the manufacturer's instructions. The following day the cells were transfected with 50 nM control or IGF1R siRNAs, and after a further 24-48 h were processed as above. Expression of the B-RAF transgene was assessed by immunoblotting for the myc tag (9B11, Cell Signaling) and total B-RAF (Santa Cruz, CA, USA).
Assays for apoptosis and survival
At 24 h after siRNA transfection, cells were reseeded into 96-well plates at 2 Â 10 4 cells per well in 100 ml complete growth medium, and caspase 3/7 activation was determined using Apo-One Caspase 3/7 assay reagent (Promega, Madison, WI, USA) according to the manufacturer's instructions. To measure cell survival under anchorage-dependent conditions, clonogenic survival assays were performed as described previously (Rochester et al., 2005) . In brief, 5 Â 10 3 transfected cells were seeded into 10 cm dishes, incubated until visible colonies were formed, and colonies were counted on a ColCount automated colony counter (Oxford Optronix, Oxford, UK). Cell survival under anchorage-independent conditions was measured in poly-HEMA-coated 24-well plates. A stock solution of 12% (w/v) polyhydroxyethylmethacrylate (poly-HEMA) (Sigma) in 95% sterile ethanol was diluted to 1.2% in 95% sterile ethanol and added to wells. After drying at room temperature for 2 h, a second coat of 6% poly-HEMA was added to the wells and left to dry overnight. At 48 h after siRNA transfection, cells were re-seeded into poly-HEMA-coated plates at 10 4 cells per well, and survival was measured 7 days later, using the CellTitre 96 3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) proliferation assay (Promega). Assays for survival and apoptosis were repeated at least three times, with three replicates on each occasion. For each transfection, immunoblotting was performed on parallel cultures to quantify IGF1R gene silencing.
Chemosensitivity assays
Cisplatin (Sigma) was dissolved in 154 mM NaCl, 5.5 mM. D-mannitol, and temozolomide (Axxora Platform, Nottingham, UK) was dissolved in PBS. Drug solutions were filtersterilized through 0.2 mm filters. Transfected melanoma cells were seeded into 24-well cell culture plates at 5 Â 10 3 cells per well in complete growth medium. After overnight incubation, cultures were treated with solvent, cisplatin or temozolomide for 24 h, following which the medium was removed and fresh medium with serum was added. Cell viability was measured 4 days later (6 days post siRNA transfection) using the CellTitre 96 MTS proliferation assay and plotted as percentage of survival in solvent-treated wells. Dose-response graphs were used to calculate IC 50 values, the concentration of cisplatin or temozolomide required to kill 50% of the cells. These assays were repeated three times, with triplicates on each occasion.
Statistical analysis
Statistical significance was tested using one-way analysis of variance followed by Bonferroni's post hoc comparisons for groupwise comparisons. Statistical calculations were performed using GraphPad Prism for Windows (version 4.00, GraphPad Software, CA, USA). 
